Breakthrough therapy is a United States Food and Drug Administration designation that expedites drug development that was created by Congress under Section 902 of the 9 July 2012 Food and Drug Administration Safety and Innovation Act.[1][2] The FDA's "breakthrough therapy" designation is not intended to imply that a drug is actually a "breakthrough" or that there is high-quality evidence of treatment efficacy for a particular condition;[3][4] rather, it allows the FDA to grant priority review to drug candidates if preliminary clinical trials indicate that the therapy may offer substantial treatment advantages over existing options for patients with serious or life-threatening diseases.[4][5] The FDA has other mechanisms for expediting the review and approval process for promising drugs, including fast track designation, accelerated approval, and priority review.[4][6]
^Darrow, JJ; Avorn, J; Kesselheim, AS (27 March 2014). "New FDA breakthrough-drug category—implications for patients". The New England Journal of Medicine. 370 (13): 1252–8. doi:10.1056/nejmhle1311493. PMID 24670173.
^Yandell, Kate (1 January 2016). "Picking Up the Pace". The Scientist.
^Schwitzer G (13 May 2016). "CBS proclaims 'cancer breakthrough' – doesn't explain what FDA means by that term". Health News Review. Archived from the original on 8 December 2020. Retrieved 9 October 2017.
^ abcKepplinger EE (February 2015). "FDA's Expedited Approval Mechanisms for New Drug Products". Biotechnol Law Rep. 34 (1): 15–37. doi:10.1089/blr.2015.9999. PMC 4326266. PMID 25713472. The fourth expedited approval mechanism—the Breakthrough Therapy designation—applies to a new drug product if it "is intended, alone or in combination with 1 or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on 1 or more clinically significant endpoints."172 In its Final Guidance, FDA has interpreted "preliminary clinical evidence" to mean evidence "sufficient to indicate that the drug may demonstrate substantial improvement in effectiveness or safety over available therapies, but in most cases is not sufficient to establish safety and effectiveness for purposes of approval."173 This generally will require more than data from in vitro studies or animal models.174 FDA expects preliminary clinical evidence to come from Phase 1 or 2 clinical trials.175
^"Fact Sheet: Breakthrough Therapies". United States Food and Drug Administration. 10 December 2014. Archived from the original on 9 October 2017. Retrieved 9 October 2017. A breakthrough therapy is a drug: • intended alone or in combination with one or more other drugs to treat a serious or life threatening disease or condition and • preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development.
^"Frequently Asked Questions: Breakthrough Therapies". Food and Drug Administration. Archived from the original on 21 January 2017. Retrieved 3 January 2017.
and 27 Related for: Breakthrough therapy information
Breakthroughtherapy is a United States Food and Drug Administration designation that expedites drug development that was created by Congress under Section...
granted "breakthroughtherapy" status, which expedites the assessment of promising drug therapies for potential approval, to psychedelic therapies using...
2018–19, the United States Food and Drug Administration (FDA) granted breakthroughtherapy designation to facilitate further research for psilocybin in the...
granted breakthroughtherapy designation (BTD) by the US Food and Drug Administration (FDA). Drugs may be listed more than once since breakthroughtherapy can...
approval based surrogate or intermediate endpoints. RMAT goes beyond breakthroughtherapy features by allowing for accelerated approval of drugs based on surrogate...
CDK inhibitor selective for CDK4 and CDK6. It was designated as a breakthroughtherapy for breast cancer by the US Food and Drug Administration (FDA) in...
talquetamab priority review, breakthroughtherapy, and orphan drug designations. In the United States, Janssen received breakthroughtherapy designation for talquetamab...
the United States Food and Drug Administration (FDA) granted the breakthroughtherapy designation to venetoclax for people with CLL or SLL who have relapsed...
commercialization rights to the drug from Genmab. Daratumumab was granted breakthroughtherapy drug status in 2013, for multiple myeloma. It was granted orphan...
was subsequently approved by the US FDA in April 2018 under the breakthroughtherapy designation for treatment of haemophila A in those who have not developed...
October 2018, the Food and Drug Administration granted psilocybin "breakthroughtherapy" status for research. The drug was granted this status again in November...
for moderate-to-severe acute pain. VX-548 has already secured FDA BreakthroughTherapy and Fast Track designations for acute pain. Vertex also plans to...
January 2022. "Celladon Receives BreakthroughTherapy Designation From FDA for Mydicar, Novel, First-in-Class Therapy in Development to Treat Heart Failure"...
associated with an improvement in sleep quality. Ulotaront was awarded a BreakthroughTherapy designation due to its increased efficacy and greatly reduced side...
the breakthroughtherapy designation. On February 3, 2015 New York-based Pfizer's drug Ibrance was approved through the FDA's BreakthroughTherapy designation...
Immunomedics announced that sacituzumab govitecan had received an FDA breakthroughtherapy designation (a classification designed to expedite the development...
August 20, 2013, it was announced that bimagrumab had received a breakthroughtherapy designation for sporadic inclusion body myositis (sIBM) by the US...
granted "breakthroughtherapy" status, which expedites the assessment of promising drug therapies for potential approval, to psilocybin therapy for treatment-resistant...
or plans to conduct these studies. Erdafitinib was also granted breakthroughtherapy designation. The FDA granted the approval of Balversa to Janssen...
long-standing and severe disease. In March 2020, the US FDA granted breakthroughtherapy designation to baricitinib for the systematic treatment of alopecia...
the application for resmetirom accelerated approval, along with breakthroughtherapy, fast track, and priority review designations. The FDA granted the...
granted the application for nirogacestat priority review, fast track, breakthroughtherapy, and orphan drug designations. The FDA granted the approval of Ogsiveo...
Food and Drug Administration (FDA) granted breakthroughtherapy designation for psilocybin-assisted therapy for treatment-resistant depression. A systematic...
were not published in medical journals. In 2017, the FDA granted breakthroughtherapy designation for its use with psychotherapy for PTSD. However, this...
disorders. In 2018–19, the Food and Drug Administration (FDA) granted BreakthroughTherapy Designation for studies of psilocybin in depressive disorders. The...
granted Fast Track Designation for pritelivir in 2017. US FDA granted BreakthroughTherapy Designation for pritelivir in 2020. Pritelivir is also known as AIC316...
Global Information